Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide
Status:
Terminated
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
Primary objective of the study is to determine the maximum tolerated dose (MTD) of bortezomib
(Velcade) in combination with rituximab, ifosfamide, carboplatin and etoposide for adult
patients with relapsed or refractory aggressive B-cell lymphoma. The secondary objectives are
to assess the tolerability and safety, the response rate, rate of autologous stem cell
transplant and CD34+ progenitor cell collection and engraftment after treatment with this
regimen.